64 related articles for article (PubMed ID: 8204951)
1. [P53 genes and malignant hematologic diseases].
Jonveaux P
Bull Cancer; 1993 Aug; 80(8):697-703. PubMed ID: 8204951
[TBL] [Abstract][Full Text] [Related]
2. p53 gene alterations in human hematological malignancies: a review.
Soussi T; Jonveaux P
Nouv Rev Fr Hematol (1978); 1991; 33(6):477-80. PubMed ID: 1818301
[TBL] [Abstract][Full Text] [Related]
3. [Mutations of the p53 gene in hematologic neoplasms].
Mori N; Mizoguchi H
Nihon Rinsho; 1992 Jun; 50(6):1353-7. PubMed ID: 1518157
[TBL] [Abstract][Full Text] [Related]
4. [p53 and hematologic malignancies].
Preudhomme C; Fenaux P
Pathol Biol (Paris); 1997 Dec; 45(10):898-908. PubMed ID: 9769955
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
6. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
7. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia.
Nakayama H; Ishimaru F; Avitahl N; Sezaki N; Fujii N; Nakase K; Ninomiya Y; Harashima A; Minowada J; Tsuchiyama J; Imajoh K; Tsubota T; Fukuda S; Sezaki T; Kojima K; Hara M; Takimoto H; Yorimitsu S; Takahashi I; Miyata A; Taniguchi S; Tokunaga Y; Gondo H; Niho Y; Harada M
Cancer Res; 1999 Aug; 59(16):3931-4. PubMed ID: 10463586
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.
Petit B; Leroy K; Kanavaros P; Boulland ML; Druet-Cabanac M; Haioun C; Bordessoule D; Gaulard P
Hum Pathol; 2001 Feb; 32(2):196-204. PubMed ID: 11230707
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor genes in normal and malignant hematopoiesis.
Krug U; Ganser A; Koeffler HP
Oncogene; 2002 May; 21(21):3475-95. PubMed ID: 12032783
[TBL] [Abstract][Full Text] [Related]
10. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of p53 mutations in hematological malignancies.
Prokocimer M; Unger R; Rennert HS; Rotter V; Rennert G
Hum Mutat; 1998; 12(1):4-18. PubMed ID: 9633814
[TBL] [Abstract][Full Text] [Related]
12. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).
De Angeli C; Gandini D; Cuneo A; Moretti S; Bigoni R; Roberti MG; Bardi A; Castoldi GL; del Senno L
Haematologica; 2000 Sep; 85(9):913-21. PubMed ID: 10980628
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma.
Nomdedéu JF; Lete I; Baiget M; Lasa A; Estivill C; Rubiol E; Badell I; Pardo N; Cubells J; Mateu R; Brunet S; Bordes R; Soler J
Haematologica; 1997; 82(5):550-4. PubMed ID: 9407719
[TBL] [Abstract][Full Text] [Related]
14. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
15. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
16. Dok1 expression and mutation in Burkitt's lymphoma cell lines.
Lee S; Huang H; Niu Y; Tommasino M; Lenoir G; Sylla BS
Cancer Lett; 2007 Jan; 245(1-2):44-50. PubMed ID: 16338067
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus.
Lee JY; Dong SM; Shin MS; Kim SY; Lee SH; Kang SJ; Lee JD; Kim CS; Kim SH; Yoo NJ
Biochem Biophys Res Commun; 1997 Aug; 237(3):667-72. PubMed ID: 9299424
[TBL] [Abstract][Full Text] [Related]
18. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia.
Güran S; Bahçe M; Beyan C; Korkmaz K; Yalçin A
Haematologia (Budap); 1998; 29(3):181-93. PubMed ID: 10069444
[TBL] [Abstract][Full Text] [Related]
19. P53 protein expression in human leukemia and lymphoma cells.
Koníková E; Kusenda J
Neoplasma; 2001; 48(4):290-8. PubMed ID: 11712681
[TBL] [Abstract][Full Text] [Related]
20. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
